Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Alan Meds vs Omada Health

Alan Meds
Graded #98

Higher grade

vs+15.499999999999993
Omada Health
Graded #435

Lower grade

The verdict

Alan Meds takes it — 71.1/100 to 55.6/100.

Alan Meds grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Telehealth platform offering compounded semaglutide and tirzepatide with multiple administration formats including microdosing and oral options.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueAlan Meds +27
72
45
Dose & formulationAlan Meds +35
75
40
Clinical oversightAlan Meds +5
82
77
Labs & monitoringOmada Health +8
53
61
FulfillmentAlan Meds +16
78
62
Contract termsEven
55
55
Alan Meds · left barOmada Health · right bar

The numbers

MetricAlan MedsOmada Health
WeighScore71.1/10055.6/100
GradeCC
Scorecard rank#98#435
Semaglutide$158/mo (compounded)Not disclosed
Tirzepatide$295/mo (compounded)Not disclosed
Coverage46 statesCoverage not published
Brand-name accessCompounded onlyCompounded only
Oral / sublingualYesInjection only
Alan Meds

Graded #98 · C

Strengths

  • Aggressively low monthly pricing
  • Both semaglutide and tirzepatide available
  • Compounded GLP-1 access
  • Multiple administration formats

Where it loses points

  • Limited public information on program details
Omada Health

Graded #435 · C

Strengths

  • Added GLP-1 prescribing and medication management in late 2025
  • Clinicians trained in obesity care, available in all 50 states
  • Behavioral support wrapped before, during and after treatment
  • GLP-1 Flex Care adds a cash-pay medication pathway in 2026
  • Publicly traded, evidence-based virtual care platform

Where it loses points

  • Core program distributed via employers and health plans, limited cash-pay
  • GLP-1 prescribing is a recent addition still scaling
  • GLP-1 Flex Care only rolling out to employers later in 2026
  • No transparent published price for the core member program

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard